Detalhe da pesquisa
1.
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.
Br J Cancer
; 126(7): 1010-1017, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903842